BACKGROUND: Human leukocyte antigen (HLA)-G is a nonclassical HLA class I molecule expressed as membrane-bound and soluble isoforms. Interaction of HLA-G with its receptor, immunoglobulin-like transcript 4 on dendritic cells (DCs) down-regulates their T-cell stimulatory ability. METHODS: We examined expression of HLA-G, immunoglobulin-like transcript 4, other immune regulatory molecules (inducible costimulator ligand and glucocorticoid-induced tumor necrosis factor-related receptor ligand), and the activation marker CMRF44 on circulating monocytoid dendritic cell (mDC) and plasmacytoid dendritic cell by monoclonal antibody staining and flow cytometry. Three groups of stable liver transplant recipients: operationally tolerant (TOL), prospective immunosuppressive drug weaning, and maintenance immunosuppression (MI) were studied, together with healthy controls (HC). Serum HLA-G levels were measured by enzyme-linked immunosorbent assay. RESULTS: In TOL patients, monocytoid dendritic cell (mDC) but not plasmacytoid dendritic cell expressed higher HLA-G than in MI patients or HC. In TOL patients, the incidence of CD4(+)CD25(hi)CD127(-) regulatory T cells (Treg) and the intensity of Treg forkhead box p3 (Foxp3) expression were significantly higher than in the MI group. HLA-G expression on circulating mDC correlated significantly with that of Foxp3 in the TOL group. There was no correlation between immunosuppressive drug (tacrolimus) dose or trough level and HLA-G expression or Treg frequency or Foxp3 expression. The incidence of patients with circulating HLA-G levels more than 100 ng/mL was highest in the TOL group, although statistical significance was not achieved. CONCLUSIONS: Higher HLA-G expression on circulating mDC in TOL recipients compared with MI or HC, suggests a possible role of HLA-G in immune regulation possibly mediated by enhanced host Treg Foxp3 expression.
BACKGROUND:Human leukocyte antigen (HLA)-G is a nonclassical HLA class I molecule expressed as membrane-bound and soluble isoforms. Interaction of HLA-G with its receptor, immunoglobulin-like transcript 4 on dendritic cells (DCs) down-regulates their T-cell stimulatory ability. METHODS: We examined expression of HLA-G, immunoglobulin-like transcript 4, other immune regulatory molecules (inducible costimulator ligand and glucocorticoid-induced tumor necrosis factor-related receptor ligand), and the activation marker CMRF44 on circulating monocytoid dendritic cell (mDC) and plasmacytoid dendritic cell by monoclonal antibody staining and flow cytometry. Three groups of stable liver transplant recipients: operationally tolerant (TOL), prospective immunosuppressive drug weaning, and maintenance immunosuppression (MI) were studied, together with healthy controls (HC). Serum HLA-G levels were measured by enzyme-linked immunosorbent assay. RESULTS: In TOL patients, monocytoid dendritic cell (mDC) but not plasmacytoid dendritic cell expressed higher HLA-G than in MI patients or HC. In TOL patients, the incidence of CD4(+)CD25(hi)CD127(-) regulatory T cells (Treg) and the intensity of Tregforkhead box p3 (Foxp3) expression were significantly higher than in the MI group. HLA-G expression on circulating mDC correlated significantly with that of Foxp3 in the TOL group. There was no correlation between immunosuppressive drug (tacrolimus) dose or trough level and HLA-G expression or Treg frequency or Foxp3 expression. The incidence of patients with circulating HLA-G levels more than 100 ng/mL was highest in the TOL group, although statistical significance was not achieved. CONCLUSIONS: Higher HLA-G expression on circulating mDC in TOL recipients compared with MI or HC, suggests a possible role of HLA-G in immune regulation possibly mediated by enhanced host TregFoxp3 expression.
Authors: P Moreau; O Faure; S Lefebvre; E C Ibrahim; M O'Brien; L Gourand; J Dausset; E D Carosella; P Paul Journal: Transplant Proc Date: 2001-05 Impact factor: 1.066
Authors: Omid Akbari; Gordon J Freeman; Everett H Meyer; Edward A Greenfield; Tammy T Chang; Arlene H Sharpe; Gerald Berry; Rosemarie H DeKruyff; Dale T Umetsu Journal: Nat Med Date: 2002-07-29 Impact factor: 53.440
Authors: Kumiko Isse; Kedar Grama; Isaac Morse Abbott; Andrew Lesniak; John G Lunz; William M F Lee; Susan Specht; Natasha Corbitt; Yoshiaki Mizuguchi; Badrinath Roysam; A J Demetris Journal: Clin Liver Dis Date: 2010-11 Impact factor: 6.126
Authors: M Takatsuki; S Uemoto; Y Inomata; H Egawa; T Kiuchi; S Fujita; M Hayashi; T Kanematsu; K Tanaka Journal: Transplantation Date: 2001-08-15 Impact factor: 4.939
Authors: M B Lutz; R M Suri; M Niimi; A L Ogilvie; N A Kukutsch; S Rössner; G Schuler; J M Austyn Journal: Eur J Immunol Date: 2000-07 Impact factor: 5.532
Authors: Heth R Turnquist; Giorgio Raimondi; Alan F Zahorchak; Ryan T Fischer; Zhiliang Wang; Angus W Thomson Journal: J Immunol Date: 2007-06-01 Impact factor: 5.422
Authors: Siqi Liu; Nicolaas A Bos; Erik A M Verschuuren; Debbie van Baarle; Johanna Westra Journal: Front Immunol Date: 2022-06-13 Impact factor: 8.786
Authors: Osamu Yoshida; Shoko Kimura; Edwin K Jackson; Simon C Robson; David A Geller; Noriko Murase; Angus W Thomson Journal: Hepatology Date: 2013-10-15 Impact factor: 17.425
Authors: Alberto Baroja-Mazo; Beatriz Revilla-Nuin; Pascual Parrilla; Laura Martínez-Alarcón; Pablo Ramírez; José Antonio Pons Journal: World J Gastroenterol Date: 2016-09-14 Impact factor: 5.742